Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 1: Challenges and Developments

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The field of clinical psychopharmacology has a long and productive history. Only recently, however, has the field begun to include children and adolescents on a larger scale. Reasons for this delay include concerns about safety and tolerability in this vulnerable population, diagnostic uncertainties, and the reluctance of the industry to embark on pediatric registration and labeling studies for diagnoses that traditionally have not been seen as predominant disorders of childhood and adolescence.’ ‹